Skeletal Muscle Hypertrophy, Fibrosis Regulation, and High-Purity Reagents for Modality Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Follistatin (FST) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Follistatin (FST-288 / FST-315) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (Native Glycosylation). |
View FST Products |
| Gene Delivery | FST Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View FST Products |
| Benchmark Ab | Anti-FST Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View FST Products |
| Validator | FST siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View FST Products |
| Related Target A | Myostatin (GDF-8) Primary therapeutic target of FST inhibition; critical for muscle hypertrophy assays. |
View Myostatin Products |
| Related Target B | Activin A High-affinity ligand neutralized by FST; key regulator of inflammation and fibrosis. |
View Activin A Products |
| Related Target C | ActRIIB The primary receptor competed by FST; essential for decoy receptor screening. |
View ActRIIB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform-specific evaluation (FST-288 vs FST-315) | Sequence-verified, isoform-specific recombinant proteins with precise C-terminal truncations. |
| Ligand cross-reactivity & selectivity screening | HEK293-expressed Activin A, Myostatin, and GDF-11 panel with verified high purity (>95%). |
| Lack of standardized clinical controls | Recombinant benchmark antibodies synthesized from peer-reviewed sequence data. |
| Off-target validation in complex matrices | Validated siRNA sets for specific target knockdown to confirm assay specificity. |
Live Follistatin (FST) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development of Follistatin (FST) is expanding rapidly beyond muscle-wasting disorders into regenerative medicine, metabolic diseases, and oncology cachexia. As a natural antagonist of Myostatin (GDF-8) and Activins, FST regulation offers a clinically validated pathway to increase skeletal muscle mass and reduce fibrotic tissue. The current clinical pipeline is transitioning from traditional protein therapies to advanced modalities, including gene therapy (AAV-mediated delivery) and modified long-acting Fc-fusion proteins. As clinical trials progress, characterizing the precise binding kinetics of FST isoforms to various TGF-beta superfamily ligands has become a primary regulatory and development milestone.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Milo Biotechnology, Kerafast | Becker Muscular Dystrophy, Sarcopenia | In vitro expression validation (Need FST Lentivirus & Specific Antibodies) |
| Fc-Fusion Proteins | Regeneron, Novartis | Muscle Atrophy, Cachexia | Ligand competition assays (Need high-purity Activin A & Myostatin) |
| Recombinant Isoforms | Academic / Clinical Consortia | Wound Healing, Osteoarthritis | Heparin-binding affinity assays (Need FST-288 vs FST-315 comparison) |